(Press-News.org) MIAMI, FLORIDA (EMBARGOED UNTIL DEC. 7, 2025, AT 6:00 P.M. EST) – Patients undergoing treatment for lymphoma often experience adverse side effects that can be so severe that they stop or slow treatment. But a new study shows that a virtual program focusing on diet and exercise is a feasible strategy for minimizing the side effects of cancer therapies and increasing treatment retention.
Early findings from the LIFE-L study will be presented on behalf of the multidisciplinary team by Melissa Lopez, Ph.D., RDN, at the American Society of Hematology (ASH) annual meeting in Orlando. Lopez is a postdoctoral associate in the CRANE Lab at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.
“A lot of the work that has been done in the area of lifestyle and oncology has been in the prevention setting or in the survivorship setting after treatment,” said Lopez, who explained that there is a significant lack of data on how lifestyle during treatment may impact treatment outcomes.
For the trial, the research team—led by Tracy Crane, Ph.D., RDN, co-lead of the Cancer Control Program and director of lifestyle medicine, prevention and digital health at Sylvester, and Craig Moskowitz, M.D., Sylvester director of academic clinician development—72 individuals were recruited and received standard, six-cycle combination chemotherapy regimens for lymphoma.
“Our goal with LIFE-L is to show that lifestyle interventions aren’t just for prevention or post-treatment—they can make a real difference during treatment. If we can help patients feel stronger and reduce side effects, we’re not only improving quality of life, we’re supporting them in completing all of their prescribed therapy, which is critical for outcomes,” said Crane.
Forty-four of those patients received immediate access to a virtual diet and exercise program designed to help them maintain their fitness and reduce the burden of side effects so that they can tolerate their prescribed cancer treatment regimen. Twenty-eight participants were placed on a waitlist control group to allow for comparison with the intervention group.
The program included weekly online coaching sessions with a registered dietitian and an exercise physiologist throughout chemotherapy. The sessions were individualized to each patient’s needs.
“We first needed to evaluate if it's feasible to do this, before even attempting to see the effects on the patients and their outcomes,” said Lopez. “We had to ask, ‘Could patients do this while they're receiving treatment?’ We can offer it all day long, but are people going to want to be a part of it? Are they able to physically and mentally be in the headspace that they want to do this?”
Not only did 81% of the eligible patients enroll in the program, but the research team found that attendance rates were high. Diet sessions had 86% attendance and exercise sessions 81%.
Those in the intervention group reported lower rates of various symptoms, including anxiety (17% vs. 34% for the waitlist group), depression (46% vs. 67%), pain (22% vs. 39%), fatigue (46% vs. 67%), and constipation (17% vs. 25%). Additionally, participants in the program demonstrated greater grip strength and outperformed waitlisted individuals on a series of physical performance tests.
As the study progresses, the team will assess whether reducing treatment burden improves participants’ adherence to their treatment plans. This is vital, as it’s well-known that interruptions due to side effects can diminish the effectiveness of cancer therapies.
“We know that if patients receive less than 85% of their prescribed chemotherapy, there are implications for survival,” said Lopez. “The goal is to keep patients above the 85% and to do that, patients need to be healthy enough to be able to tolerate the dose that was prescribed.”
Lopez hopes that presenting the LIFE-L findings at ASH will encourage more clinicians to refer their patients to lifestyle medicine programs. She aims to highlight the importance of diet and exercise to hematologist-oncologists, as there is often a lack of knowledge or awareness about available recommendations for patients. The virtual program is designed to help bridge this gap.
“It's been very, very rewarding to see the physicians referring patients,” said Lopez. “The physicians are key stakeholders in all of this.”
about Sylvester research on the InventUM blog and follow @SylvesterCancer on X for the latest news on its research and care.
# # #
Poster Title: Feasibility and preliminary efficacy of a Mediterranean diet and home-based exercise intervention during chemotherapy for lymphoma survivors: The LIFE-L study
Date, Time and Location: Dec. 7, 2025, 6-8 P.M. EST, OCCC – West Halls B3-B4
END
Insect pupae hiss like snakes for defense. A Kobe University team now reveals the mechanisms, opening the door to further studies involving predator reactions to defensive sounds.
Just as you would shout or make noise to drive off a perceived threat, some insects have been known to produce defensive sounds. Some moths, for example, have been observed producing sounds to ward off predators at multiple developmental stages; pupal sound production has so far been attributed mainly to physical friction between body parts. “We became interested in this topic when ...
(ORLANDO, Dec. 7, 2025) In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venetoclax compared with conventional induction chemotherapy. The azacitidine–venetoclax combination (known as aza-ven) is the standard of care for older adults who are not fit enough for intensive chemotherapy. The trial is the first to test the superiority of this regimen to intensive induction chemotherapy, the current standard for fit patients.
“Our study met ...
(ORLANDO, Dec. 7, 2025) In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction in the risk of death or disease progression if they received epcoritamab in addition to the standard second-line regimen versus the standard regimen alone. The study is the first reported randomized controlled trial to test a bispecific antibody combination in follicular lymphoma and suggests the combination could offer an effective alternative to chemotherapy that can be safely administered on an outpatient basis.
Based on the study results, the U.S. Food and Drug Administration (FDA) approved epcoritamab with ...
(ORLANDO, Dec. 7, 2025) A chemotherapy-free combination treatment outperformed a combination of targeted therapy and chemotherapy among patients with Ph+ acute lymphoblastic leukemia (ALL) in a new study. The phase III trial, which included adult patients with no upper age limit, is the first formal comparison of the efficacy and safety of these two approaches in newly diagnosed patients with Ph+ ALL.
Researchers say the findings offer reassurance that chemotherapy can be omitted without detrimental effects and suggest that a chemo-free targeted agent and immunotherapy combination could become the new standard of care for this patient group.
“The chemo-free approach ...
(ORLANDO, Dec. 7, 2025) Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib, a covalent BTK inhibitor. Based on the study results, researchers suggest pirtobrutinib shows promise as initial BTK inhibitor therapy, including in the frontline setting, for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Non-covalent BTK inhibitors were initially developed to overcome resistance to covalent ...
University of Cincinnati researchers will present research at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition Dec. 6 to 9 in Orlando.
Phase 1 data testing new CLL treatment encouraging
A class of drugs called BTK inhibitors have become a standard treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). However, the prevalence of new resistance mutations has created a need for new treatments in patients with relapsed CLL who progressed through approved standard of care options, said the Cancer Center’s Zulfa Omer, MD.
“This is an area of unmet need, with current options providing ...
MIAMI, FLORIDA (EMBARGOED UNTIL DEC. 6, 2025, AT 2:00 P.M. EST) – Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine. The findings will be presented Dec. 6, 2025, at the American Society of Hematology (ASH) annual meeting in Orlando.
None of the 18 patients who completed up to six cycles of treatment with the antibody linvoseltamab had detectable disease on highly sensitive tests. This preliminary ...
Article Summary:
Researchers found that DNA’s shape matters. When its loops break, cancer can start.
Based on a new concept of architectural tumor suppression, researchers used proteins that organize DNA to also help prevent lymphoma.
Artificial intelligence helped reveal the changes that could guide future treatments.
MIAMI, FLORIDA (EMBARGOED UNTIL DEC. 6, 2025, AT 9:50 A.M. EST) – Cancer isn’t just about broken genes—it’s about broken architecture. Imagine a city where roads suddenly vanish, ...
Article Summary
ACCESS study reveals patients can safely receive stem cell transplants from unrelated donors with multiple genetic mismatches.
A protective regimen acts as a “bridge,” preventing complications and boosting survival rates.
Findings could make transplants accessible to nearly all patients with blood cancers, regardless of ancestry.
Study will be presented at ASH Dec. 8 and will also be highlighted in a special ASH press briefing Dec. 6 at 8:30AM EST.
MIAMI, FLORIDA (EMBARGOED UNTIL DEC. 6, 2025, AT 8:30AM) – For years, the ...
(ORLANDO, Dec. 6, 2025) A new study shows that giving the chemotherapy drug cyclophosphamide after allogeneic hematopoietic cell transplantation, a curative treatment for common types of blood cancer, can make the procedure safe and effective even when donors and recipients are unrelated and have extensive genetic mismatches. Historically, genetic compatibility has played a primary role in identifying matched donors; these results suggest that many patients who need a transplant could now have access to a much broader pool of potential donors and expect outcomes comparable to those from fully matched donors.
The study found that one-year survival was similar whether patients received ...
